Analytical Methods and Arrays for Use in the Same
AssigneeSenzagen AB
InventorsMalin Lindstedt, Carl Borrebaeck, Henrik Johansson, Ann-Sofie Albrekt
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro method for identifying agents capable of inducing respiratory sensitization in a mammal and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in Table 1A, Table 1B and/or Table 1C in MUTZ-3 cells exposed to a test agent.
Claims74
A method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of:
- a) exposing a population of dendritic cells or a population of dendritic-like cells to a test agent;
- and
- b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table 1A and/or Table 1B;
- wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the sensitizing effect of the sample to be tested.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of one or more biomarkers defined in Table 1A, for example, at least 2 of the biomarkers defined in Table 1A.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of OR5B21.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of SLC7A7.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of OR5B21 and SLC7A7.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers defined in Table 1B, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 of the biomarkers defined in Table 1B.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table 1B.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of one or more of the biomarkers defined in Table 10, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286 or 287 of the biomarkers defined in Table 10.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table 1C.
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of all of the biomarkers defined in Table 1.
The method according to any one of the preceding claims wherein step (b) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarker(s).
The method according to any one of the preceding claims wherein measuring the expression of the one or more biomarker(s) in step (b) is performed using one or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table 1.
The method according to any one of claims 20 to 23 wherein the one or more binding moieties are 5 to 100 nucleotides in length.
The method according to any one of the preceding claims wherein step (b) is performed using an array.
The method according to any one of the preceding claims for identifying agents capable of inducing a respiratory hypersensitivity response.
The method according to any one of the preceding claims wherein the hypersensitivity response is a humoral hypersensitivity response.
The method according to any one of the preceding claims for identifying agents capable of inducing respiratory allergy.
The method according to any one of the preceding claims wherein the population of dendritic cells or population of dendritic-like cells is a population of dendritic-like cells.
The method according to any one of the preceding claims wherein the dendritic-like cells are MUTZ-3 cells.
The method according to any one of the preceding claims wherein the one or more negative control agent provided in step (c) is selected from the group consisting of 1-butanol, 4-aminobenzoic acid, chlorobenzene, dimethyl formamide, ethyl vanillin, isopropanol, methyl salicylate, propylene glycol, potassium permanganate, Tween 80™ (polyoxyethylene (20) sorbitan monooleate) and zinc sulphate.
The method according to any one of the preceding claims wherein the one or more positive control agent provided in step (e) comprises or consists of one or more agent selected from the group consisting of ammonium hexachloroplatinate, ammonium persulfate, glutaraldehyde, hexamethylen diisocyanate, maleic anhydride, methylene diphenol diisocyanate, phtalic anhydride, toluendiisocyanate and trimellitic anhydride.
The method according to any one of the preceding claims wherein the method is indicative of the sensitizing potency of the sample to be tested.
Use of two or more biomarkers selected from the group defined in Table 1 in combination for identifying respiratory hypersensitivity response sensitising agents.
An analytical kit according to claim 76 further comprising one or more control samples.
A method or use substantially as described herein.
An array or kit substantially as described herein.
Dependencies are inferred from the claim text.